343TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial
Machiels J, Shin S, Cohen E, Harrington K, Burtness B, Gause C, Swift A, Swaby R, Le Tourneau C. 343TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial. Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.30.Peer-Reviewed Original Research13TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial
Harrington K, Machiels J, Shin S, Cohen E, Burtness B, Gause C, Swift A, Swaby R, Le Tourneau C. 13TiP Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial. Annals Of Oncology 2015, 26: viii5. DOI: 10.1093/annonc/mdv514.03.Peer-Reviewed Original ResearchKEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.
Cohen E, Machiels J, Harrington K, Burtness B, Shin S, Gause C, Swift A, Brown H, Perrone A, Cheng J, Swaby R, Le Tourneau C. KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. Journal Of Clinical Oncology 2015, 33: tps6084-tps6084. DOI: 10.1200/jco.2015.33.15_suppl.tps6084.Peer-Reviewed Original Research